AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03270748
Drug: GvHD prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 50 mg/kg intravenously day+3 and +4 (total dose:100 mg/kg).
Trial: NCT00298714
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00206141
Drug: Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00264407
Drug: Hormone Replacement Therapy - HRT
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03728244
Drug: MEBO ointment
DrugBank: Formebolone (DB01569)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacological effects of MEBO are attributable to beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensi, Beeswax and sesame oil (Zhang et al., 2005).
Trial: NCT03728244
Drug: Hyaluronic Acid gel
RxNorm normalized name: HYALURONATE SODIUM 3.5 mg in 1 mL TOPICAL GEL [Hyaluronic Acid Gel]
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints. The hyaluronic acid that is used as medicine is extracted from rooster combs or made by bacteria in the laboratory.
Trial: NCT01552343
Drug: Desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
Trial: NCT00070447
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00070447
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02981290
Drug: CellCept
RxNorm normalized name: Cellcept
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
Trial: NCT03034941
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg twice per day per os for 12 weeks
Trial: NCT01409694
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
Trial: NCT03034941
Drug: Liraglutide + metformin
RxNorm normalized name: Liraglutide
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the COMBI group the initial dose of metformin was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg twice per day. Liraglutide 1.2 mg once per day s.c. was added after first two weeks of monotherapy with metformin.
Trial: NCT03633331
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03633331
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03633331
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IM
Trial: NCT05821543
Drug: metformin+sibutramine
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 tablet (850 mg + 10 mg) once per day in the morning, without chewing and followed with a glass of water, during meals, for 180 days. At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit1 (Day 1), the zero dose was increased to 1 tablet (850 mg + 15 mg)
Trial: NCT05821543
Drug: sibutramine+ microcrystalline cellulose
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule (10 mg + 158.5 mg) once per day in the morning, without chewing and followed with a glass of water, during meals for, 180 days.At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit 1 (Day 1), the zero dose was increased to 1 capsule (15 mg + 153,5 mg)
Trial: NCT02090543
Drug: Phenprocoumon (Marcumar)
RxNorm normalized name: phenprocoumon
DrugBank: Phenprocoumon (DB00946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: common use, no requirements (real life situation)
Trial: NCT02090543
Drug: Rivaroxaban (Xarelto, BAY-59 7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: common use, no requirements (real life situation)
Trial: NCT01009294
Drug: Ataluren
RxNorm normalized name: Ataluren
DrugBank: Ataluren (DB05016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Oral powder
Trial: NCT01203488
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 IU (0.1 ml) was given on Mondays, Wednesdays, and Fridays for four weeks.
Trial: NCT02974244
Drug: exenatide once weekly
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: exenatide treatment in the customary clinical care in the USA
Trial: NCT02974244
Drug: basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: basal insulin treatment in the customary clinical care in USA
Trial: NCT00393822
Drug: palifermin
RxNorm normalized name: palifermin
DrugBank: Palifermin (DB00039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles
Trial: NCT02596776
Drug: Propranolol and fat biopsy
RxNorm normalized name: Hard fat
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subset of subjects will receive propranolol and have fat biopsy performed
Trial: NCT01824602
Drug: Eslicarbazepine acetate 1800 mg
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Trial: NCT01824602
Drug: Eslicarbazepine acetate 1200 mg
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Trial: NCT01824602
Drug: Eslicarbazepine acetate 600 mg
RxNorm normalized name: eslicarbazepine acetate 600 MG
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Trial: NCT00351715
Drug: Sublingual Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00604578
Drug: Pioglitazone Hydrochloride
RxNorm normalized name: Pioglitazone Hydrochloride
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03429075
Drug: Psilocybin + Placebo
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dosing days psilocybin vs 6 weeks of daily placebo
Trial: NCT03429075
Drug: Psilocybin + Escitalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple dosing days psilocybin vs 6 weeks of daily escitalopram
Trial: NCT00032929
Drug: Selegiline
RxNorm normalized name: Selegiline
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00215254
Drug: quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01346800
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4
Trial: NCT01346800
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4 in presence of ritonavir
Trial: NCT01615510
Drug: Tapentadol immediate release
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg, single administration
Trial: NCT02603575
Drug: caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70mg ivdrip the first day, then 50mg ivdrip qd
Trial: NCT02603575
Drug: Sulfanilamides
DrugBank: Sulfanilamide (DB00259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.92g q8h
Trial: NCT01912534
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40, 80 and 160 mg tablets of Valsartan
Trial: NCT00839111
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400mg twice daily from d3 to d14,d17-28
Trial: NCT00337948
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03019549
Drug: Lanabecestat
RxNorm normalized name: Lanabecestat
DrugBank: Lanabecestat (DB14814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00469937
Drug: lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
Trial: NCT02607228
Drug: Alobresib
RxNorm normalized name: Alobresib
DrugBank: Alobresib (DB14970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily.
Trial: NCT02607228
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsules administered orally once daily.
Trial: NCT00390832
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU
Trial: NCT02226484
Drug: Quercetin
RxNorm normalized name: Quercetin
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 250 mg capsules of quercetin twice-a-day one hour before meals with a glass of water.
Trial: NCT03969017
Drug: pegylated interferon (Peg IFN)α-2b
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not tolerate the side effects of Peg IFNα-2b). Peg IFNα-2b treatment will be performed until HBsAg \<0.05IU/ml, with a maximum duration of 48 weeks.
Trial: NCT02128490
Drug: Febuxostat IR
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat IR over-encapsulated tablets
Trial: NCT02128490
Drug: Febuxostat XR
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat over-encapsulated capsules
Trial: NCT02128490
Drug: Febuxostat placebo
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat IR and XR placebo-matching capsules
Trial: NCT02128490
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine tablets
Trial: NCT02128490
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole capsules
Trial: NCT02243176
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of saxaglitpin will be 5mg oral qd.
Trial: NCT02243176
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.
Trial: NCT03232112
Drug: Exenatide 2 MG Injection
RxNorm normalized name: exenatide 2 MG Injection
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection once-weekly
Trial: NCT01409694
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
Trial: NCT00419250
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01495819
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5cc's of saline give at least once.
Trial: NCT01495819
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).
Trial: NCT00565955
Drug: montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:~5-12 years: 5 mg chewable tablet of montelukast; \> 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid.
Trial: NCT01364415
Drug: Pasireotide LAR
RxNorm normalized name: pasireotide LAR 20 MG Injection
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03319628
Drug: upifitamab rilsodotin
RxNorm normalized name: Upinitatug rilsodotin
DrugBank: Upinitatug rilsodotin (DB19104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536
Trial: NCT00473694
Drug: sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as an intravenous (IV) infusion
Trial: NCT00473694
Drug: neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as an IV infusion
Trial: NCT00473694
Drug: vecuronium
RxNorm normalized name: Vecuronium
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as an IV infusion
Trial: NCT00473694
Drug: rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as an IV infusion
Trial: NCT00473694
Drug: glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an IV infusion
Trial: NCT00469079
Drug: Nicotine gum and lozenge
RxNorm normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement
Trial: NCT02602509
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02602509
Drug: Pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01409694
Drug: Vitamin D placebo
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
Trial: NCT03941444
Drug: ANAVEX2-73
RxNorm normalized name: ANAVEX2-73
DrugBank: Blarcamesine (DB05592)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral solution
Trial: NCT04057443
Drug: Hematologic Drug
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
Trial: NCT00015548
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00015548
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00015548
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00015548
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00388089
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose level A: 1 mg/m2; Dose level B: 1.3 mg/m2; Dose level C: 1.6 mg/m2; Dose level D: 1.6 mg/m2
Trial: NCT00388089
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose level A: 3 mg/m2; Dose level B: 3 mg/m2; Dose level C: 3 mg/m2; Dose level D: 4 mg/m2
Trial: NCT03026803
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02030561
Drug: Trastuzumab + NK cells
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03802721
Drug: Brussels sprouts before 50 ng dose
RxNorm normalized name: BRUSSELS SPROUT
DrugBank: Brussels sprout (DB10642)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brussels sprouts for 7 days before 50 ng (5.4 nCi) dose of BaP
Trial: NCT03802721
Drug: DIM supplement before 50 ng dose
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIM supplement for 7 days before 50 ng (5.4 nCi) dose of BaP and coadministration with DIM supplement
Trial: NCT00117962
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC = 5 q 21 days for 4 cycles
Trial: NCT00117962
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
Trial: NCT00506389
Drug: Esmirtazapine
RxNorm normalized name: Esmirtazapine
DrugBank: Esmirtazapine (DB06678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name corn starch), magnesium stearate, and lactose monohydrate.
Trial: NCT01057628
Drug: ipragliflozin
RxNorm normalized name: ipragliflozin
DrugBank: Ipragliflozin (DB11698)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT01011257
Drug: Asprin
RxNorm normalized name: Easprin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
Trial: NCT01011257
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: clopidogrel 75 mg bid
Trial: NCT03427437
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
Trial: NCT03427437
Drug: Adrenalin
RxNorm normalized name: Adrenalin
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin